Welcome to the Seagen grant management system. Use this online system to request support from Seagen Inc. for Independent Medical Education (IME), Investigator-Sponsored Trials (IST), Preclinical Proposals and Charitable Grants.
Seagen is committed to conducting business in compliance with all its policies, American Medical Association ("AMA") Guidelines on Gifts to Physicians, the AMA Ethical Opinion on Independent Medical Education, the Pharmaceutical Research and Manufacturers of America ("PhRMA") code on Interactions with Healthcare Professionals, the Accreditation Council for Independent Medical Education ("ACCME") Standards for Commercial Support, the U.S. Food and Drug Administration ("FDA") regulations and guidance, the U.S. Department of Health and Human Services' Office of Inspector General ("OIG") guidance and all applicable federal and state laws and regulations.
To begin the request process, please log in to our system using your User ID and Password on the left side of the screen. If you are a first time user, please click on the link below "Need a User ID?" to begin the registration and application process.
Independent Medical Education Grants
Seagen Inc. is pleased to announce its launch of a new Medical Education Grant portal on January 19th, 2021. To navigate to IME iEnvision, please click the linkhere.
Seagen is committed to supporting innovative, high quality, independent accredited and unaccredited medical education for healthcare professionals and/or patients that addresses unmet medical needs, fosters clinical excellence, and improves health outcomes in areas of interest to our company. A program supported by an educational grant must be for scientific and educational purposes only and not considered a commercial or corporate sponsorship. For more information on independent medical education grants, please see ourProgram Overview
Seagen is currently accepting applications in the following therapeutic areas:
- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma
- Urothelial (Bladder) Cancer
- Cervical Cancer
- Breast Cancer
Seagen has identified independent healthcare education gaps for each of the supported therapeutic areas that align with our business needs, impact HCP knowledge, competence, and application and positively contribute to improving healthcare for patients.
Call for Grant Applications: None currently active
Our Investigator-Sponsored Trials (IST) program provides support for external clinical research that advances medical and/or scientific knowledge about our products to enhance patient care. Our current IST portfolio includes programs investigating brentuximab vedotin in lymphoma and tucatinib in breast and other HER2-expressing cancers. Other research areas may be considered with strong scientific rationale.
Enfortumab vedotin proposals must be from the United States and are reviewed jointly by Seagen and Astellas. To submit a proposal related to enfortumab vedotin research, please visit theAstellas Investigator-Sponsored Research portal.
The objective of the Seagen IST program is to provide funding and/or study drug for clinical research that will:
- Address unmet medical need with new scientific data, and
- Support pilot studies that explore the feasibility of investigational treatments.
For additional information regarding support for ISTs, please see ourProgram Overview
To discuss your proposed research or for questions about our process, please contact your regional Medical Science Liaison (MSL) or email us atIST@seagen.com
for help in identifying the MSL in your region.
Requests for materials transfer or sponsored research will be considered, with a limited number of projects supported each year. To discuss your proposal prior to submission, please contact your MSL directly. For assistance in identifying the MSL for your territory, please contact IST@seagen.com
For all grant types please note:
- You can save your request submission at any stage of the process and return to complete your request application at a later time.
- Seagen will generally review your request for completion, clarity, and compliance within 45-60 days of submission.
- You will receive an email notification upon approval or denial of your request.
- If approved, funding is conditioned on the requirement to provide budget reconciliation within 90 days following completion of your event, activity or IST.
- If funding was not used for the approved purpose and a refund is due to Seagen, you will have 30 days after submitting your reconciliation to submit the refund.
- Failure to complete the reconciliation and/or submit the refund within the allocated timeframes may result in your inability to submit future requests for funding, in addition to any rights or remedies available to Seagen.